A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)
研究概览
简要总结
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
详细描述
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat children who have relapsed or refractory (r/r) anaplastic large-cell lymphoma (sALCL) or Hodgkin lymphoma (HL). This study will look at the maximum tolerated dose and/or recommended phase 2 dose, safety and pharmacokinetics of brentuximab vedotin along with overall response of people who took brentuximab vedotin.
The study enrolled 36 patients. In the phase 1 portion of the study, 12 participants were enrolled to receive brentuximab vedotin 1.4-1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.
Once the maximum tolerated dose and/or recommended phase 2 dose and pharmacokinetics of brentuximab vedotin was reached, participants were enrolled by diagnosis into two phase 2 study arms: relapsed or refractory sALCL or relapsed or refractory HL and received brentuximab vedotin 1.8 mg/kg as 30-minute IV on Day 1 of every 21-day cycle for up to 16 cycles. One participant received a maximum of 20 cycles at the joint discretion of the sponsor and the investigator for continued clinical benefit.
This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 5 years. Participants made multiple visits to the clinic, and were contacted by telephone every 12 weeks for 12 months after the end of treatment (EOT) for progression free survival and then every 6 months until death, study closure, or 2 years after enrollment of the last participant for overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants aged 2 to <18 years (5 to <18 years for Hodgkin lymphoma [HL])
- •Diagnosis of systemic anaplastic large-cell lymphoma (sALCL), or HL for which standard, curative, life-prolonging, or palliative treatment does not exist or is no longer effective
- •Participants with sALCL must have documented anaplastic lymphoma kinase (ALK) status and must be beyond first remission or refractory to front-line chemotherapy
- •Participants diagnosed with any relapsed or refractory CD30+ hematologic malignancy (e.g., primary mediastinal B-cell lymphoma) may be included in phase 1 of the study
- •Participants with HL must be in their second of later relapse, have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy, and were ineligible for, refused, or previously received a stem cell transplant
- •Performance score ≥ 60 from Lansky Play Performance Scale if ≤16 years
- •Negative pregnancy test
- •Fertile Participants must use 2 effective methods of contraception prior to and through 6 months after the last dose of the study drug
排除标准
- •Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible)
- •Received an allogeneic stem cell transplant <3 months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participant
- •Receiving immunosuppressive therapy
- •Receiving systemic therapy for chronic graft-versus-host disease (topical therapy is allowed)
- •Previous treatment with any anti-CD30 antibody
- •Therapeutic monoclonal antibody use within the longer of 6 weeks or 5 plasma half-lives
- •Systemic cardiac disease that would, in the opinion of the investigator or medical monitor, interfere with assessment of efficacy or safety of the drug
- •History of another primary malignancy not in remission for at least 3 years (the following are exempt from the 3-year limit: nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)
- •Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML
- •History of cirrhosis
- •Active systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable)
- •Concurrent therapy with other anti-neoplastic or experimental agents
- •Systemic corticosteroid therapy <7 days prior to first dose of the study medication
- •Any serious underlying medical condition that, in the opinion of the investigator or medical monitor, would impair their ability to receive or tolerate the planned treatment
- •Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation
- •Received nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to the first study dose
- •Prior autologous hematopoietic stem cell infusion <4 weeks prior to first study dose
- •Grade 2 or greater unresolved toxicity from prior antineoplastic therapy
- •Grade 2 or greater peripheral neuropathy
- •Female participants who are both lactating and breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug
- •Received local palliative radiation therapy <14 days prior to the first dose of study medication
- •Received radiation therapy to more than 25% of the bone marrow-containing spaces < 84 days prior to first dose of study medication
- •Received a strong or listed moderate inhibitor of CYP3A4 <2 weeks prior to first study dose
- •Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
研究组 & 干预措施
Brentuximab vedotin: Phase 1
Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
干预措施: Brentuximab vedotin (Drug)
Brentuximab vedotin: Phase 2
Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
干预措施: Brentuximab vedotin (Drug)
结局指标
主要结局
Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1)
时间窗: From the first dose through 30 days after the last dose of study medication (Up to 15 months)
Abnormal clinical laboratory values (serum chemistry and hematology) were reported as AEs if they were considered by the investigator to be a clinically significant change from Baseline or led to premature discontinuation of study treatment, dose modification, or other therapeutic intervention.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1)
时间窗: From the first dose through 30 days after the last dose of study medication (Up to 15 months)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. AE severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
Serum Concentration of Total Antibodies (Conjugated and Unconjugated) (Phase 1)
时间窗: Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
Blood samples were collected and tested for conjugated and unconjugated antibodies.
Number of Participants With Clinically Significant Vital Signs Values Reported as AEs (Phase 1)
时间窗: From the first dose through 30 days after the last dose of study medication (Up to 15 months)
Vital signs measurements included supine (after 3-5 minutes in this position) and standing (after 3-5 minutes in this position) measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.
Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1)
时间窗: Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
Blood samples were collected and tested for serum concentrations of brentuximab vedotin antibody-drug conjugate.
Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1)
时间窗: Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose
Blood samples were collected and tested for MMAE plasma concentrations.
Overall Response Rate (ORR) (Phase 1 and 2)
时间窗: Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or end of treatment (EOT) (Up to 15 months)
Overall response rate is defined as the percentage of participants with complete remission (CR) or partial remission (PR) as assessed by an independent review facility (IRF) using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
次要结局
- Overall Response Rate (ORR) (Phase 1)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT (Up to 15 months))
- Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing ATA (nATA) (Phase 1 and 2)(Baseline up to EOT (Up to 15 months))
- Time to Progression (TTP) (Phase 1 and 2)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death (Up to 27 months))
- Time to Response (Phase 1 and 2)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT (Up to 15 months))
- Duration of Response (DOR) (Phase 1 and 2)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death or end of study (Up to 72 months))
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1 and 2)(From the first dose through 30 days after the last dose of study medication (up to 15 months))
- Number of Participants With Clinically Significant Vital Signs Reported as AEs (Phase 1 and 2)(From the first dose through 30 days after the last dose of study medication (Up to 15 months))
- Antibody-drug Conjugate (ADC) Serum Concentrations (Phase 1 and 2)(Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose)
- Monomethyl Auristatin E (MMAE) Plasma Concentrations (Phase 1 and 2)(Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose)
- Event Free Survival (EFS) (Phase 1 and 2)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death (Up to 27 months))
- Progression Free Survival (PFS) (Phase 1 and 2)(Cycles 2, 4, 7, 10, 13 and 16 (21-day cycles) until disease progression, death or EOT and then every 12 weeks for 12 months after EOT, until disease progression, or death or end of study (Up to 72 months))
- Overall Survival (OS) (Phase 1 and 2)(Every 6 months after EOT, until the sooner of death, study closure, or 2 years after enrolment of the last participant (Up to 72 months))
- Number of Participants With Abnormal Clinical Laboratory Values Reported as AEs (Phase 1 and 2)(From the first dose through 30 days after the last dose of study medication (Up to 15 months))
- Serum Concentration of Total Antibodies (Conjugated and Unconjugated)(Cycle 1 and 8 pre-dose and 5 minutes, 24, 48, 96 and 312 hours post-dose; Cycle 2 pre-dose, 5 minutes and 24, 48 and 96 hours post-dose; Cycle 3 to 16 pre-dose and 5 minutes post-dose)